NCT06909253 - Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Myasthenia Gravis, Generalized

Interventions

DRUG

Ravulizumab

Ravulizumab, concentrate for solution for infusion

Trial Locations (12)

RECRUITING

Research Site, Bydgoszcz

NOT_YET_RECRUITING

Research Site, Bydgoszcz

RECRUITING

Research Site, Gdansk

NOT_YET_RECRUITING

Research Site, Katowice

NOT_YET_RECRUITING

Research Site, Krakow

RECRUITING

Research Site, Krakow

RECRUITING

Research Site, Lodz

RECRUITING

Research Site, Lublin

WITHDRAWN

Research Site, Poznan

RECRUITING

Research Site, Szczecin

RECRUITING

Research Site, Warsaw

RECRUITING

Research Site, Wroclaw